Dermatitis News

Immune Pharmaceuticals recently provided an update on treatments for atopic dermatitis and psoriasis as part of its first quarter financial report.

Dermata announced the first phase 1 pharmacokinetic study of its lead compound, DMT210, for treating moderate-to-severe rosacea.

Papular eruptions and other mucocutaneous findings were linked to confirmatory testing for Zika virus infection, according to study results recently published in JAMA Dermatology.

Children with a history of atopic dermatitis were more likely to display food sensitization during food challenge, according to recent research.

Researchers identified an increased risk for Parkinson’s disease in patients with rosacea, according to data published in JAMA Neurology.

A survey completed by members of the World Allergy Organization indicate heterogeneity among allergists and dermatologists when performing the skin patch test, according to recent research.

Systemic dupilumab monotherapy significantly reduced moderate-to-severe atopic dermatitis symptoms in two phase 3 clinical trials, Regeneron Pharmaceuticals Inc. and Sanofi announced in a press release.

Patients with psoriasis, atopic dermatitis or healthy skin appear to have significant different skin microbiota compositions, according to recent research.

The National Rosacea Society has designated April as Rosacea Awareness month to educate the public to the chronic facial disorder estimated to affect more than 16 million Americans, according to a news release.

LOS ANGELES — Two phase 3 studies presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting confirmed that the investigational crisaborole topical ointment, 2%, was safe and effective for patients with mild-to-moderate atopic dermatitis.